Y08060
CAS No. 2222565-19-5
Y08060 ( Y 08060 )
Catalog No. M13549 CAS No. 2222565-19-5
Y08060 is a potent and selective BET inhibitor with Kd of 306 nM for BRD4 BD1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameY08060
-
NoteResearch use only, not for human use.
-
Brief DescriptionY08060 is a potent and selective BET inhibitor with Kd of 306 nM for BRD4 BD1.
-
DescriptionY08060 is a potent and selective BET inhibitor with Kd of 306 nM for BRD4 BD1, displays excellent selectivity for BET subfamily over other non-BET family with the exception of moderate inhibition of CBP/EP300; esuppresses cell growth, colony formation, and expression of androgen receptor (AR), AR regulated genes, and MYC in prostate cancer cell lines. such as C4-2B, LNCaP, and 22Rv1; demonstrates good PK profile with high oral bioavailability (61.54%).
-
SynonymsY 08060
-
PathwayChromatin/Epigenetic
-
TargetBromodomain
-
RecptorBromodomain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2222565-19-5
-
Formula Weight471.32
-
Molecular FormulaC18H19BrN2O6S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name5-bromo-2-methoxy-N-(6-methoxy-2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xiang Q, et al. ACS Med Chem Lett. 2018 Feb 13;9(3):262-267.
molnova catalog
related products
-
GS-626510
GS-626510 (GS-6510, GS 6510, GS 626510) is anovel BET family bromodomains inhibitor with Kd of 0.5-2.8 nM for BRD2/3/4, and BRDT.
-
GW 841819X
GW 841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomain.
-
Mivebresib
Mivebresib (ABBV-075) is a potent and orally available BET bromodomain inhibitor with Ki of 1.0, 12.2, 1.5, and 2.2 nM for BRD2, BRD3, BRD4 and BRDT, respectively.